1. Non-melanoma skin cancer as a possible adverse event due to anti-interleukin-6 treatment
- Author
-
HF Lorentzen, Mogens Pfeiffer-Jensen, Jef Diernaes, and M Heje
- Subjects
Male ,musculoskeletal diseases ,Oncology ,Skin/pathology ,medicine.medical_specialty ,Skin Neoplasms ,Biopsy ,Immunology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Tocilizumab ,Rheumatology ,Internal medicine ,medicine ,Carcinoma ,Skin Squamous Cell Carcinoma ,Humans ,Immunology and Allergy ,030212 general & internal medicine ,Immunosuppression/adverse effects ,skin and connective tissue diseases ,Interleukin 6 ,Adverse effect ,Melanoma ,Skin ,Immunosuppression Therapy ,030203 arthritis & rheumatology ,biology ,Interleukin-6 ,business.industry ,General Medicine ,Middle Aged ,Skin Neoplasms/chemically induced ,Rhinoplasty ,medicine.disease ,Combined Modality Therapy ,Interleukin-6/adverse effects ,stomatognathic diseases ,chemistry ,Rheumatoid arthritis ,biology.protein ,Rhinoplasty/methods ,Skin cancer ,business ,Non melanoma - Abstract
We report the first case of tocilizumab (TCZ)-attributable skin squamous cell carcinoma (SCC) in a 53-year-old male with rheumatoid arthritis (RA).Figure 1. (A) Ulceration: suspected carcinoma on t...
- Published
- 2018
- Full Text
- View/download PDF